These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17010056)

  • 1. An update on breast cancer prevention trials.
    Wickerham DL; Fourchotte V
    Int J Gynecol Cancer; 2006; 16 Suppl 2():498-501. PubMed ID: 17010056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of breast cancer using SERMs and aromatase inhibitors.
    Strassmer-Weippl K; Goss PE
    J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):5-18. PubMed ID: 14587860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of breast cancer.
    Zelnak AB; O'Regan RM
    Curr Probl Cancer; 2004; 28(4):201-17. PubMed ID: 15318323
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
    Bentrem DJ; Jordan VC
    Curr Opin Obstet Gynecol; 2002 Feb; 14(1):5-12. PubMed ID: 11801870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
    Twombly R
    J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
    [No Abstract]   [Full Text] [Related]  

  • 6. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer prevention in high-risk women: searching for new options.
    Nelson NJ
    J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
    [No Abstract]   [Full Text] [Related]  

  • 9. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
    JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for Primary Prevention of Breast Cancer.
    Shieh Y; Tice JA
    JAMA; 2020 Jul; 324(3):291-292. PubMed ID: 32692377
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemoprevention of breast cancer.
    O'Regan RM
    Lancet; 2006 Apr; 367(9520):1382-3. PubMed ID: 16650636
    [No Abstract]   [Full Text] [Related]  

  • 12. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
    Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
    J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer Risk-Reducing Medications.
    Graham D; DiNome ML; Ganz PA
    JAMA; 2020 Jul; 324(3):310. PubMed ID: 32692388
    [No Abstract]   [Full Text] [Related]  

  • 14. Breast cancer risk reduction therapy: the low-hanging fruit.
    Bevers TB
    J Natl Compr Canc Netw; 2015 Apr; 13(4):376-8. PubMed ID: 25870373
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Bao T; Prowell T; Stearns V
    Am J Ther; 2006; 13(4):337-48. PubMed ID: 16858170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor modulators and prevention of invasive breast cancer.
    Gradishar WJ; Cella D
    JAMA; 2006 Jun; 295(23):2784-6. PubMed ID: 16754726
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of breast cancer: current state of the science and future opportunities.
    Uray IP; Brown PH
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
    Lippman SM; Brown PH
    J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.